What is ALNY's last price and market cap on Chartloom?

The overview shows a last price near n/a and market cap near 22.10B (subject to data latency), alongside the price snapshot and profile on this page.

What P/E and 52-week range are shown for ALNY?

P/E (TTM) is 37.54 and 52-week range is $197.81 to $485.36 when available from the data feed; see the metrics and chart on this page.

Where do Chartloom’s ALNY figures come from?

Figures are compiled from market data and SEC-backed fundamentals used in the app. Use primary filings and a broker for trading decisions.

What trailing-twelve-month financials does Chartloom show for ALNY?

The company profile lists revenue (TTM) near $4.65B, net income (TTM) near $783M, EPS (TTM) near $5.88 when available from the market-data feed. Figures are informational and may lag live markets.

Where is Alnylam Pharmaceuticals, Inc. based, and what identifiers does Chartloom list?

The company context section lists headquarters in Cambridge, Massachusetts, US, 133.9M shares outstanding, ISIN US02043Q1076 when available from company profile and filing metadata.

Please enable JavaScript to continue using this application.

Alnylam Pharmaceuticals, Inc.

$ALNY

Health Care · Biotechnology

IR Run Scenarios

Overview Charts AI Summary Financials Valuation

Profile

Read AI summary

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the business of developing and commercializing novel therapeutics based on ribonucleic acid interference. The company is headquartered in Cambridge, Massachusetts and currently employs 2,500 full-time employees. The company went IPO on 2004-05-28. The firm is engaged in discovering, developing, manufacturing and commercializing novel therapeutics based on ribonucleic acid interference (RNAi). Its marketed products include AMVUTTRA (vutrisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis (hATTR) in adults ; ONPATTRO (patisiran) for the treatment of the polyneuropathy of hATTR amyloidosis in adults; GIVLAARI (givosiran) for the treatment of adults with acute hepatic porphyria; OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1, and Leqvio (inclisiran), which is being developed and commercialized by its partner, Novartis AG, for the treatment of adults with hypercholesterolemia or mixed dyslipidemia. The Company’s clinical development programs include Cemdisiran, Zilebesiran, Elebsiran, Mivelsiran, ALN-6400, and ALN-HTT02. The company is developing Cemdisiran to treat complement-mediated diseases.

Employees

2,500

Website

www.alnylam.com/

IPO

2004-05-28

Beta

Next earnings date

—

Financials & valuation

Open valuation

Revenue (TTM)

Net income (TTM)

EPS (TTM)

P/E (price / listing EPS)

P/S (TTM)

Forward P/E

Forward P/S

EV / EBITDA

PEG (TTM)

FCF yield (TTM)

Gross margin (TTM)

Net margin (TTM)

Forward revenue growth (NTM)

Dividend / share (TTM)

Dividend yield (TTM)

Payout ratio (TTM)

Dividend growth (5Y)

Company context

Exchange

NASDAQ NMS - GLOBAL MARKET

ISIN

US02043Q1076

Headquarters

Cambridge, Massachusetts, US

Shares outstanding

133.9M

NAICS sector

Manufacturing

Institutional ownership

101.63%

Browse other companiesFree AI scores and summaries for more stocks